Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
Abstract Background The DYNAMIC trial investigated the use of circulating tumor DNA (ctDNA) to guide adjuvant treatment decisions in stage II colon cancer. Despite the DYNAMIC trial’s assertion that a ctDNA-guided approach could minimize the use of adjuvant treatment without compromising recurrence-...
Main Authors: | Timothée Olivier, Alyson Haslam, Vinay Prasad |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12916-023-03037-9 |
Similar Items
-
Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment
by: Timothée Olivier, et al.
Published: (2022-11-01) -
ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
by: Mahendra Naidoo, et al.
Published: (2021-01-01) -
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
by: Susanna Slater, et al.
Published: (2023-03-01) -
Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
by: Fulong Wang, et al.
Published: (2023-12-01) -
Basic ctDNA Panel Promises Affordable Clinical Validity in Colon Cancer Patients but Not in Pancreas Cancer Patients
by: Mandy Radefeldt, et al.
Published: (2023-11-01)